Luts & Greenleigh Group’s Pfizer PFE Stock Holding History

Luts & Greenleigh Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,355	Closed	-$207K	–	107
2026 Q1	$207K	Buy	+7,355	New	+$196K	0.16%	88
2024 Q4	–	Sell	-6,997	Closed	-$202K	–	82
2024 Q3	$202K	Buy	+6,997	New	+$204K	0.19%	84

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Luts & Greenleigh Group's PFE Position: Q2 2026 in Review

Luts & Greenleigh Group sold out of Pfizer (PFE) in Q2 2026, closing a stake of 7,355 shares — an estimated $207K sold.

Luts & Greenleigh Group first reported a position in PFE in Q3 2024 and held it in 2 quarters. The position peaked at $207K in Q1 2026. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Luts & Greenleigh Group reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
Luts & Greenleigh Group sold 7,355 Pfizer shares in Q2 2026, an estimated $207K.
Luts & Greenleigh Group first reported a position in Pfizer in Q3 2024 and held it in 2 quarters.
Luts & Greenleigh Group's Pfizer position peaked at $207K in Q1 2026.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Luts & Greenleigh Group's 13F filing for Q2 2026, filed 7 Aug 2026.